MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 16.03.2026
Zomedica Corp. Kurzfristige Verbindlichkeiten 2011-2026 | ZOM
Kurzfristige Verbindlichkeiten Jährlich Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.45 M | 9.33 M | 9.03 M | 7.81 M | 4.34 M | 2.03 M | 2.09 M | 2.38 M | 829 K | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 9.45 M | 829 K | 5.25 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
2.65 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.02 | - | $ 110 M |  Canada |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
128 M | $ 11.77 | 1.99 % | $ 836 M | USA |
 |
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
75.3 M | $ 5.04 | 0.6 % | $ 325 M | USA |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.06 | 0.66 % | $ 43 M | USA |
 |
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
96.3 M | $ 34.91 | 2.38 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
651 M | $ 8.33 | 3.22 % | $ 426 M | USA |
 |
China Pharma Holdings
CPHI
|
5.02 M | $ 0.62 | 2.94 % | $ 10.8 M |  China |
 |
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.58 | -2.27 % | $ 340 M | USA |
 |
Pacira BioSciences
PCRX
|
310 M | $ 22.69 | -2.45 % | $ 1.05 B | USA |
 |
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | USA |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
1.01 B | $ 9.72 | 4.4 % | $ 1.35 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
23 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.4 | -2.24 % | $ 2.98 M | USA |
 |
Relmada Therapeutics
RLMD
|
12.2 M | $ 6.18 | 4.57 % | $ 186 M | USA |
 |
Rockwell Medical
RMTI
|
16.6 M | $ 0.96 | 6.61 % | $ 22.4 M | USA |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 0.9 | 4.68 % | $ 44.9 M | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
6.85 M | $ 2.17 | - | $ 22.7 M | USA |
 |
Solid Biosciences
SLDB
|
30.3 M | $ 7.48 | 2.33 % | $ 305 M | USA |
 |
Veru
VERU
|
11.9 M | $ 2.37 | -0.84 % | $ 320 M | USA |
 |
Tilray
TLRY
|
433 M | $ 6.9 | 0.15 % | $ 4.26 B | Canada |
 |
Viatris
VTRS
|
6.75 B | $ 13.51 | - | $ 16.2 B | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 0.72 | 1.41 % | $ 3.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |